| 2 | 1/1 | 返回列表 |
| 查看: 660 | 回復(fù): 1 | ||
zoujing10銅蟲 (小有名氣)
|
[求助]
精氨酸布洛芬默克索引
|
| 誰手上有默克索引,幫我查一下精氨酸布洛芬的內(nèi)容 |

專家顧問 (著名寫手)
|
Structural Formula Vector Image Title: Ibuprofen CAS Registry Number: 15687-27-1 CAS Name: a-Methyl-4-(2-methylpropyl)benzeneacetic acid Additional Names: p-isobutylhydratropic acid; (±)-2-(4-isobutylphenyl)propionic acid Manufacturers' Codes: RD-13621 Trademarks: Advil (Wyeth); Brufen (Abbott); Brufort (Lampugnani); Dolgit (Dolorgiet); Dolocyl (Novartis); Epobron (Ono); Fenbid (Goldshield); Gynofug (Wolff); Ibumetin (Nycomed); Ibutop (Dolorgiet); Ipren (Pharmacia); Motrin (McNeil); Napacetin (Toyama); Novogent (Temmler); Nuprin (BMS); Nurofen (Boots); Opturem (Kade); Proflex (Novartis); Solufen (SMB); Tabalon (Teofarma); Urem (Kade) Molecular Formula: C13H18O2 Molecular Weight: 206.28 Percent Composition: C 75.69%, H 8.80%, O 15.51% Literature References: Nonsteroidal anti-inflammatory drug (NSAID); activity resides primarily in the (S)-isomer. Prepn: J. S. Nicholson, S. S. Adams, GB 971700; eidem, US 3385886 (1964, 1968 both to Boots Pure Drug); T. Shiori, N. Kawai, J. Org. Chem. 43, 2936 (1978); J. T. Pinhey, B. A. Rowe, Tetrahedron Lett. 21, 965 (1980). Methods for resolution of enantiomers: R. Bhushan, J. Martens, Biomed. Chromatogr. 12, 309 (1998). HPLC determn in plasma: R. Canaparo et al., ibid. 14, 219 (2000). Pharmacology: S. S. Adams et al., Arch. Int. Pharmacodyn. Ther. 178, 115 (1969). Acute toxicity: G. Orzalesi et al., Arzneim.-Forsch. 27, 1006 (1977). Clinical trial for closure of patent ductus arteriosus: B. Van Overmeire et al., N. Engl. J. Med. 343, 674 (2000). Review of pharmacology and clinical experience: M. Busson et al., J. Int. Med. Res. 14, 53-62 (1986); of clinical pharmacokinetics and metabolism: N. M. Davies, Clin. Pharmacokinet. 34, 101-154 (1998). Properties: Colorless, crystalline stable solid, mp 75-77°. Relatively insol in water. Readily sol in most organic solvents. LD50 in male mice, rats (mg/kg): 495, 626 i.p.; 1255, 1050 orally (Orzalesi). Melting point: mp 75-77° Toxicity data: LD50 in male mice, rats (mg/kg): 495, 626 i.p.; 1255, 1050 orally (Orzalesi) Derivative Type: Lysine salt Trademarks: Arfen (Lisapharma); Imbun (Merckle) Molecular Formula: C13H18O2.C6H14N2O2 Molecular Weight: 352.47 Percent Composition: C 64.74%, H 9.15%, O 18.16%, N 7.95% Derivative Type: S-Form L-lysine salt monohydrate CAS Registry Number: 141505-32-0 Additional Names: Dexibuprofen lysine Manufacturers' Codes: MK-223 Molecular Formula: C13H18O2.C6H14N2O2.H2O Molecular Weight: 370.48 Percent Composition: C 61.60%, H 9.25%, O 21.59%, N 7.56% Therap-Cat: Anti-inflammatory; analgesic; antipyretic. Therap-Cat-Vet: Anti-inflammatory. Keywords: Anti-inflammatory (Nonsteroidal); Arylpropionic Acid Derivatives. |
| 2 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 求調(diào)劑323材料與化工 +4 | 1124361 2026-03-24 | 4/200 |
|
|---|---|---|---|---|
|
[考研] 287求調(diào)劑 +10 | 晨昏線與星海 2026-03-19 | 11/550 |
|
|
[考研] 085601求調(diào)劑總分293英一數(shù)二 +3 | 鋼鐵大炮 2026-03-24 | 3/150 |
|
|
[考研] 300分,材料,求調(diào)劑,英一數(shù)二 +5 | 超贊的 2026-03-24 | 5/250 |
|
|
[考博] 26申博自薦 +3 | whh869393 2026-03-24 | 3/150 |
|
|
[基金申請] 請教下大家 2026年國家基金申請是雙盲審嗎? +3 | lishucheng1 2026-03-22 | 5/250 |
|
|
[考研] 341求調(diào)劑(一志愿湖南大學(xué)070300) +5 | 番茄頭--- 2026-03-22 | 6/300 |
|
|
[考研] 工科0856求調(diào)劑 +5 | 沐析汀汀 2026-03-21 | 5/250 |
|
|
[考研] 求老師收我 +3 | zzh16938784 2026-03-23 | 3/150 |
|
|
[考研]
|
酥酥魚.. 2026-03-21 | 4/200 |
|
|
[考研] 352求調(diào)劑 +3 | 大米飯! 2026-03-22 | 3/150 |
|
|
[考研] 一志愿西安交通大學(xué)材料工程專業(yè) 282分求調(diào)劑 +11 | 楓橋ZL 2026-03-18 | 13/650 |
|
|
[考研] 308求調(diào)劑 +3 | 墨墨漠 2026-03-21 | 3/150 |
|
|
[考研] 311求調(diào)劑 +3 | 26研0 2026-03-20 | 3/150 |
|
|
[考研] 求調(diào)劑 +3 | 13341 2026-03-20 | 3/150 |
|
|
[考研] 311求調(diào)劑 +3 | 勇敢的小吳 2026-03-20 | 3/150 |
|
|
[考研] 一志愿南昌大學(xué),327分,材料與化工085600 +9 | Ncdx123456 2026-03-19 | 9/450 |
|
|
[考研] 321求調(diào)劑 +9 | 何潤采123 2026-03-18 | 11/550 |
|
|
[考研] 一志愿西安交通大學(xué) 學(xué)碩 354求調(diào)劑211或者雙一流 +3 | 我想要讀研究生 2026-03-20 | 3/150 |
|
|
[考研]
|
不想起名字112 2026-03-19 | 3/150 |
|